$MIRM
Mirum Pharmaceuticals, Inc. Stock $mirm

$mirm Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000175942524000019 Filed on May 08, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$77.88M	$69.22M	$31.60M
YoY Change	107.68%	119.07%	145.1%
Cost Of Revenue	$20.23M	$17.83M	$4.979M
YoY Change	196.93%	258.1%	105.4%
Gross Profit	$57.65M	$51.39M	$26.62M
YoY Change	87.87%	93.07%	154.29%
Gross Profit Margin	74.03%	74.24%	84.24%
Selling, General & Admin	$49.21M	$45.64M	$30.22M
YoY Change	49.35%	51.02%	58.08%
% of Gross Profit	85.36%	88.8%	113.52%
Research & Development	$32.67M	$32.22M	$23.55M
YoY Change	48.45%	36.84%	-2.24%
% of Gross Profit	56.67%	62.7%	88.46%
Depreciation & Amortization	$5.854M	$5.664M	$1.337M
YoY Change	338.17%	323.64%	290.94%
% of Gross Profit	10.15%	11.02%	5.02%
Operating Expenses	$102.1M	$95.69M	$58.75M
YoY Change	65.3%	62.89%	28.75%
Operating Profit	-$24.23M	-$26.47M	-$27.15M
YoY Change	-0.17%	-2.5%	-17.07%
Interest Expense	-$83.00K	$56.00K	-$1.970M
YoY Change	-16.16%	-102.84%	-46.83%
% of Operating Profit
Other Income/Expense, Net	$312.0K	$1.757M	-$811.0K
YoY Change	-213.87%	-316.65%	426.62%
Pretax Income	-$24.00M	-$24.66M	-$29.93M
YoY Change	-67.44%	-17.62%	-18.22%
Income Tax	$635.0K	$624.0K	$201.0K
% Of Pretax Income
Net Earnings	-$24.64M	-$25.28M	-$30.13M
YoY Change	-66.72%	-16.1%	-17.69%
Net Earnings / Revenue	-31.64%	-36.52%	-95.35%
Basic Earnings Per Share	-$0.52	-$0.54	-$0.80
Diluted Earnings Per Share	-$0.52	-$0.54	-$0.80
COMMON SHARES
Basic Shares Outstanding	47.13M shares	47.00M	37.95M
Diluted Shares Outstanding	47.24M shares	46.93M shares	37.68M

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$278.4M	$302.8M	$132.1M
YoY Change	-15.63%	129.3%	-5.6%
Cash & Equivalents	$233.2M	$302.8M	$49.42M
Short-Term Investments	$45.13M		$82.65M
Other Short-Term Assets	$8.590M	$10.02M	$8.987M
YoY Change	-11.71%	11.46%	52.12%
Inventory	$20.44M	$21.61M	$6.613M
Prepaid Expenses
Receivables	$60.43M	$55.00M	$24.66M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$367.8M	$389.5M	$172.3M
YoY Change	-4.09%	125.99%	10.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.101M	$501.0K	$877.0K
YoY Change	27.14%	-42.87%	-2.34%
Goodwill
YoY Change
Intangibles	$261.8M	$257.4M	$57.70M
YoY Change	363.82%	346.21%	212.19%
Long-Term Investments	$17.08M
YoY Change
Other Assets	$3.972M	$3.873M	$1.337M
YoY Change	244.49%	189.68%	-34.24%
Total Long-Term Assets	$292.9M	$262.5M	$161.2M
YoY Change	387.64%	62.84%	31.18%
TOTAL ASSETS
Total Short-Term Assets	$367.8M	$389.5M	$172.3M
Total Long-Term Assets	$292.9M	$262.5M	$161.2M
Total Assets	$660.8M	$652.0M	$333.5M
YoY Change	48.96%	95.47%	19.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$9.842M	$15.98M	$6.440M
YoY Change	-31.87%	148.18%	30.29%
Accrued Expenses	$101.4M	$89.57M	$40.40M
YoY Change	137.5%	121.71%	50.28%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$112.3M	$105.9M	$48.84M
YoY Change	92.96%	116.84%	41.36%
LONG-TERM LIABILITIES
Long-Term Debt	$307.2M	$306.8M	$0.00
YoY Change	0.53%
Other Long-Term Liabilities	$3.972M	$4.287M	$772.0K
YoY Change	39620.0%	455.31%	7620.0%
Total Long-Term Liabilities	$3.972M	$4.287M	$772.0K
YoY Change	39620.0%	455.31%	7620.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$112.3M	$105.9M	$48.84M
Total Long-Term Liabilities	$3.972M	$4.287M	$772.0K
Total Liabilities	$431.8M	$417.4M	$192.4M
YoY Change	18.3%	116.95%	13.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$606.2M	-$581.5M	-$423.0M
YoY Change	21.97%	37.47%	43.98%
Common Stock	$835.6M	$816.1M	$564.0M
YoY Change	45.19%	44.71%	40.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$229.0M	$234.6M	$141.2M
YoY Change
Total Liabilities & Shareholders Equity	$660.8M	$652.0M	$333.5M
YoY Change	48.96%	95.47%	19.91%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$24.64M	-$25.28M	-$30.13M
YoY Change	-66.72%	-16.1%	-17.69%
Depreciation, Depletion And Amortization	$5.854M	$5.664M	$1.337M
YoY Change	338.17%	323.64%	290.94%
Cash From Operating Activities	-$3.803M	$15.21M	-$33.77M
YoY Change	63.15%	-145.04%	-14.86%
INVESTING ACTIVITIES
Capital Expenditures	$10.78M	$13.00K	$41.00K
YoY Change	-28.46%	-68.29%
Acquisitions
YoY Change
Other Investing Activities	-$61.94M	$0.00	$42.06M
YoY Change	-222.37%	-100.0%	15.22%
Cash From Investing Activities	-$72.72M	-$13.00K	$42.02M
YoY Change	-304.57%	-100.03%	15.11%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.291M	$1.205M	12.99M
YoY Change	-93.64%	-90.72%	-28.26%
NET CHANGE
Cash From Operating Activities	-3.803M	$15.21M	-33.77M
Cash From Investing Activities	-72.72M	-$13.00K	42.02M
Cash From Financing Activities	7.291M	$1.205M	12.99M
Net Change In Cash	-69.23M	$16.52M	21.42M
YoY Change	-146.8%	-22.88%	43.42%
FREE CASH FLOW
Cash From Operating Activities	-$3.803M	$15.21M	-$33.77M
Capital Expenditures	$10.78M	$13.00K	$41.00K
Free Cash Flow	-$14.58M	$15.20M	-$33.82M
YoY Change	-16.19%	-144.95%	-14.76%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001759425
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2024Q1	dei	Amendment Flag AmendmentFlag	false
CY2024Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	0	usd
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Foster City
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94404
CY2024Q1	dei	City Area Code CityAreaCode	650
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	667-4085
CY2024Q1	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001 per share
CY2024Q1	dei	Trading Symbol TradingSymbol	MIRM
CY2024Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	47133021	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	302843000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	54999000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	67968000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	21606000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	22312000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10017000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10935000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	389465000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	387541000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	501000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	706000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	680000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1284000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	257443000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	252925000	usd
CY2024Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3873000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4165000	usd
CY2024Q1	us-gaap	Assets Assets	651962000	usd
CY2023Q4	us-gaap	Assets Assets	646621000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	15983000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7416000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	89568000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	78544000	usd
CY2024Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	358000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1104000	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	105909000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	87064000	usd
CY2024Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	328000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	617000	usd
CY2024Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	306835000	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	306421000	usd
CY2024Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4287000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3849000	usd
CY2024Q1	us-gaap	Liabilities Liabilities	417359000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	397951000	usd
CY2024Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2024Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	47061106	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	47061106	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	46723143	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	46723143	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	5000	usd
CY2024Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	816129000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	803260000	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-581518000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-556239000	usd
CY2024Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-13000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1644000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	234603000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	248670000	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	651962000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	646621000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	69222000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31598000	usd
CY2024Q1	mirm	Cost Of Sales CostOfSales	17830000	usd
CY2023Q1	mirm	Cost Of Sales CostOfSales	4979000	usd
CY2024Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	32222000	usd
CY2023Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	23548000	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	45638000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	30219000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	95690000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	58746000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-26468000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-27148000	usd
CY2024Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	3633000	usd
CY2023Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	2272000	usd
CY2024Q1	mirm	Other Nonoperating Interest Expense OtherNonoperatingInterestExpense	3577000	usd
CY2023Q1	mirm	Other Nonoperating Interest Expense OtherNonoperatingInterestExpense	4242000	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1757000	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-811000	usd
CY2024Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24655000	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29929000	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	624000	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	201000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-25279000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30130000	usd
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.54
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.54
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.80
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.80
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	46927550	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	46927550	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	37675306	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37675306	shares
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-25279000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-30130000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	165000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-1657000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	188000	usd
CY2024Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26936000	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29777000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	248670000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11664000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-25279000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	-1657000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	234603000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	142037000	usd
CY2023Q1	mirm	Stock Issued During Period Value Contingent Milestone Achievement StockIssuedDuringPeriodValueContingentMilestoneAchievement	4292000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8728000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Before Tax Portion Attributable To Parent OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent	353000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	141150000	usd
CY2024Q1	us-gaap	Profit Loss ProfitLoss	-25279000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-30130000	usd
CY2024Q1	us-gaap	Share Based Compensation ShareBasedCompensation	11450000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	8561000	usd
CY2024Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5664000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1337000	usd
CY2024Q1	mirm	Inventory Reserves And Firm Purchase Commitment Losses Under Operating Activity InventoryReservesAndFirmPurchaseCommitmentLossesUnderOperatingActivity	-237000	usd
CY2023Q1	mirm	Inventory Reserves And Firm Purchase Commitment Losses Under Operating Activity InventoryReservesAndFirmPurchaseCommitmentLossesUnderOperatingActivity	0	usd
CY2024Q1	mirm	Cost Recognized On Sale Of Acquired Inventory CostRecognizedOnSaleOfAcquiredInventory	2209000	usd
CY2023Q1	mirm	Cost Recognized On Sale Of Acquired Inventory CostRecognizedOnSaleOfAcquiredInventory	0	usd
CY2024Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	414000	usd
CY2023Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	usd
CY2024Q1	mirm	Non Cash Interest Expense On Revenue Interest Purchase Agreement NonCashInterestExpenseOnRevenueInterestPurchaseAgreement	0	usd
CY2023Q1	mirm	Non Cash Interest Expense On Revenue Interest Purchase Agreement NonCashInterestExpenseOnRevenueInterestPurchaseAgreement	4242000	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1734000	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	0	usd
CY2024Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-518000	usd
CY2023Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	153000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-12969000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	667000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-918000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	40000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3173000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	778000	usd
CY2024Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-11000	usd
CY2023Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-285000	usd
CY2024Q1	mirm	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	11277000	usd
CY2023Q1	mirm	Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities	-1212000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-269000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-219000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	15212000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18774000	usd
CY2024Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	usd
CY2023Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	22444000	usd
CY2024Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	0	usd
CY2023Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	64500000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13000	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	41000	usd
CY2024Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	15000000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-13000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	27015000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	14480000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1205000	usd
CY2023Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	1390000	usd
CY2024Q1	mirm	Repayment Of Revenue Interest RepaymentOfRevenueInterest	0	usd
CY2023Q1	mirm	Repayment Of Revenue Interest RepaymentOfRevenueInterest	-2883000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1205000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12987000	usd
CY2024Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	113000	usd
CY2023Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	188000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	16517000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	21416000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	286326000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	128003000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	302843000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	149419000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	289000	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	262000	usd
CY2024Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	139000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2024Q1	mirm	Accrued Milestone Payments Classified As Intangible Assets Net AccruedMilestonePaymentsClassifiedAsIntangibleAssetsNet	10000000	usd
CY2023Q1	mirm	Accrued Milestone Payments Classified As Intangible Assets Net AccruedMilestonePaymentsClassifiedAsIntangibleAssetsNet	0	usd
CY2024Q1	mirm	Inventory Purchases In Accrued Liabilities InventoryPurchasesInAccruedLiabilities	-1731000	usd
CY2023Q1	mirm	Inventory Purchases In Accrued Liabilities InventoryPurchasesInAccruedLiabilities	103000	usd
CY2024Q1	mirm	Right Of Use Asset And Lease Liabilities Decrease Due To Lease Modification RightOfUseAssetAndLeaseLiabilitiesDecreaseDueToLeaseModification	723000	usd
CY2023Q1	mirm	Right Of Use Asset And Lease Liabilities Decrease Due To Lease Modification RightOfUseAssetAndLeaseLiabilitiesDecreaseDueToLeaseModification	0	usd
CY2024Q1	mirm	Stock Based Compensation Capitalized To Inventory StockBasedCompensationCapitalizedToInventory	214000	usd
CY2023Q1	mirm	Stock Based Compensation Capitalized To Inventory StockBasedCompensationCapitalizedToInventory	167000	usd
CY2024Q1	mirm	Stock Issued During Period Value Contingent Milestone Achievement StockIssuedDuringPeriodValueContingentMilestoneAchievement	0	usd
CY2023Q1	mirm	Stock Issued During Period Value Contingent Milestone Achievement StockIssuedDuringPeriodValueContingentMilestoneAchievement	4292000	usd
CY2024Q1	mirm	Deferred Offering Costs In Accrued Liabilities DeferredOfferingCostsInAccruedLiabilities	0	usd
CY2023Q1	mirm	Deferred Offering Costs In Accrued Liabilities DeferredOfferingCostsInAccruedLiabilities	240000	usd
CY2024Q1	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2018-05-02
CY2024Q1	mirm	Number Of Approved Medicines NumberOfApprovedMedicines	3	medicine
CY2024Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-581500000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	302800000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	302800000	usd
CY2023Q1	mirm	Accrued Milestone Payments Current AccruedMilestonePaymentsCurrent	15000000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ materially from those estimates. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s unaudited condensed consolidated financial statements as of and for the three months ended March 31, 2024 reflect the Company’s estimates of the impact of the geopolitical and macroeconomic environment, including the impact of inflation, bank failures, high interest rates and foreign exchange rate fluctuations. The duration and the scope of these conditions cannot be predicted; therefore, the extent to which these conditions will directly or indirectly impact the Company’s business, results of operations and financial condition, is uncertain. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities as of the date of this filing.</span></div>
CY2022Q4	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	100000000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	302843000	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49419000	usd
CY2024Q1	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	0	usd
CY2023Q1	us-gaap	Restricted Cash Equivalents RestrictedCashEquivalents	100000000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	302843000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	149419000	usd
CY2024Q1	mirm	Investments Classified As Cash And Cash Equivalent Original Maturities InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities	P3M
CY2024Q1	mirm	Fair Value Of Its Investments Related To Credit Loss FairValueOfItsInvestmentsRelatedToCreditLoss	0	usd
CY2024Q1	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	usd
CY2024Q1	mirm	Purchase Commitments PurchaseCommitments	5300000	usd
CY2023Q4	mirm	Purchase Commitments PurchaseCommitments	5200000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	276590000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	19147000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	257443000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P11Y10M24D
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	266590000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	13665000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	252925000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Asset Useful Life FiniteLivedIntangibleAssetUsefulLife	P12Y3M18D
CY2024Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5500000	usd
CY2023Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1300000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	17023000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	22698000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	22590000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	22375000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	22375000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	150382000	usd
CY2024Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	257443000	usd
CY2024Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	69222000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31598000	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1700000	usd
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22537933	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10671320	shares
CY2024Q1	mirm	Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis	281865000	usd
CY2024Q1	mirm	Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2024Q1	mirm	Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2024Q1	mirm	Cash Equivalents And Available For Sale Securities Debt Securities CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities	281865000	usd
CY2024Q1	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	281865000	usd
CY2024Q1	mirm	Cash Equivalents And Available For Sale Securities Debt Securities CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities	281865000	usd
CY2023Q4	mirm	Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis	278116000	usd
CY2023Q4	mirm	Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2023Q4	mirm	Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	usd
CY2023Q4	mirm	Cash Equivalents And Available For Sale Securities Debt Securities CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities	278116000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	278116000	usd
CY2023Q4	mirm	Cash Equivalents And Available For Sale Securities Debt Securities CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities	278116000	usd
CY2023Q1	mirm	Available For Sale Securities Gross Realized Gain Loss Net1 AvailableForSaleSecuritiesGrossRealizedGainLossNet1	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0	usd
CY2023Q1	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q1	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	2886000	usd
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	2998000	usd
CY2024Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	10850000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	9873000	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7870000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	9441000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	21606000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	22312000	usd
CY2024Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	12040000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	20939000	usd
CY2024Q1	mirm	Accrued Sales Deductions Current AccruedSalesDeductionsCurrent	30005000	usd
CY2023Q4	mirm	Accrued Sales Deductions Current AccruedSalesDeductionsCurrent	23650000	usd
CY2024Q1	mirm	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	7678000	usd
CY2023Q4	mirm	Accrued Clinical Trials Current AccruedClinicalTrialsCurrent	7268000	usd
CY2024Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	9318000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7941000	usd
CY2024Q1	mirm	Accrued Contract Manufacturing And Non Clinical Costs Current AccruedContractManufacturingAndNonClinicalCostsCurrent	8599000	usd
CY2023Q4	mirm	Accrued Contract Manufacturing And Non Clinical Costs Current AccruedContractManufacturingAndNonClinicalCostsCurrent	9922000	usd
CY2024Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	6657000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	6716000	usd
CY2024Q1	us-gaap	Interest Payable Current InterestPayableCurrent	5271000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	2108000	usd
CY2024Q1	mirm	Accrued Milestone Payments Current AccruedMilestonePaymentsCurrent	10000000	usd
CY2023Q4	mirm	Accrued Milestone Payments Current AccruedMilestonePaymentsCurrent	0	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	89568000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	78544000	usd
CY2023Q2	mirm	Stock Issued During Period Shares Indemnification Holdback Liability StockIssuedDuringPeriodSharesIndemnificationHoldbackLiability	31631	shares
CY2019Q1	us-gaap	Area Of Land AreaOfLand	5600	sqft
CY2019Q1	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P4Y
CY2019Q1	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P5Y
CY2019Q1	mirm	Tenant Improvement Allowance TenantImprovementAllowance	400000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.080
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y10M24D
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y10M24D
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	350000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	127000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	114000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	114000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	57000	usd
CY2024Q1	mirm	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	0	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	762000	usd
CY2024Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	76000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	686000	usd
CY2024Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000	usd
CY2023Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	200000	usd
CY2020Q3	mirm	Maximum Amount Of Sale Covered In Shelf Registration Statement MaximumAmountOfSaleCoveredInShelfRegistrationStatement	300000000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	200000	usd
CY2024Q1	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	200000	usd
CY2024Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	26610595	shares
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	24145170	shares
CY2024Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11450000	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8561000	usd

Files In Submission

Name	View Source	Status
0001759425-24-000019-index-headers.html	Edgar Link	pending
0001759425-24-000019-index.html	Edgar Link	pending
0001759425-24-000019.txt	Edgar Link	pending
0001759425-24-000019-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_1.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mirm-10qq124xexx101.htm	Edgar Link	pending
mirm-10qq124xexx102.htm	Edgar Link	pending
mirm-10qq124xexx105.htm	Edgar Link	pending
mirm-10qq124xexx311.htm	Edgar Link	pending
mirm-10qq124xexx312.htm	Edgar Link	pending
mirm-10qq124xexx321.htm	Edgar Link	pending
mirm-10qq124xexx322.htm	Edgar Link	pending
mirm-20240331.htm	Edgar Link	pending
mirm-20240331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
mirm-20240331_def.xml	Edgar Link	unprocessable
mirm-20240331_cal.xml	Edgar Link	unprocessable
mirm-20240331_lab.xml	Edgar Link	unprocessable
mirm-20240331_pre.xml	Edgar Link	unprocessable
mirm-20240331_htm.xml	Edgar Link	completed
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MIRM
Mirum Pharmaceuticals, Inc. Stock $mirm

2024 Q2 Form 10-Q Financial Statement

#000175942524000019 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MIRM Mirum Pharmaceuticals, Inc. Stock $mirm

2024 Q2 Form 10-Q Financial Statement

#000175942524000019 Filed on May 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MIRM
Mirum Pharmaceuticals, Inc. Stock $mirm